TeraRecon Debuts Next Generation Northstar(TM) AI Explorer at SIIM18
National Harbor, Maryland - May 31st, 2018, May 31, 2018 (GLOBE NEWSWIRE) -- TeraRecon (www.terarecon.com) today announced that its first-of-kind Northstar(TM) AI Explorer has reached a new milestone that allows physicians to interact with individual measurements, markings, and findings created by AI image processing algorithms. To demonstrate the potential of these AI-assisted workflows, the company is previewing an end-to-end cardiac MR analysis workflow in partnership with EnvoyAI (www.envoyai.com) and Corstem (www.corstem.ai) that provides highly automated results while keeping the physician informed and in control. The new Northstar features are the latest in a rapid progression of technological achievements made as the product evolves from a results viewer to a more powerful and integrated AI interaction and observation portal.
The new Northstar AI Explorer(TM) provides the ability to not only accept or reject certain images and reports created by AI, as Northstar has done previously, but now empowers physicians to fine-tune findings and interrogate the clinical assumptions that underlie the results in AI-generated reports. The system is composed of a web-based user interface that works seamlessly alongside or within the physicians' current PACS, EMR, and enterprise viewing systems.
The Northstar AI Explorer and the EnvoyAI platform together form an application framework upon which any 3rd party algorithm developer can build. "TeraRecon strives to make AI-assisted medical imaging interpretations more accessible to physicians by offering an unprecedented level of transparency into AI functionality along with deep integrations into existing workflows that optimize ease of use and efficiency. By exposing the key clinical assumptions that these AI machines are making and stopping to collect physician feedback before proceeding, we reduce risk while accelerating innovation and clinical adoption", said Jeff Sorenson, President and CEO of TeraRecon.
The cardiac MR analysis workflow prototype is composed of Corstem AI-generated anatomic contours and clinical assumptions being quickly verified or adjusted. The physician feedback is sent to the Corstem application hosted on the EnvoyAI platform. The workflow then completes the cardiac function and fully quantitative pixel-wise perfusion analyses, marks updated findings in the images, and generates the report. The physician can make further adjustments and send the results to the permanent archive, such as the PACS or VNA.
"The most exciting aspect of the Northstar AI Explorer is that physicians can appreciate the quality of the AI findings", said Pascal Labrecque, Chief Operating Officer of Corstem. Pascal continued, "Our proprietary deep learning algorithm performs cardiac MR contouring with some of the most sophisticated motion correction technology available. The combination of TeraRecon's Northstar AI Explorer and the EnvoyAI platform allows cutting-edge AI technology to really shine."
The trained AI algorithms are not continuously learning from physician feedback in real-time, to ensure that tight version-control and testing regimens are maintained. However, with permission and appropriate data sharing protocols from the healthcare institution, their anonymized image data and physician ground truthing feedback may be shared and used by the algorithm developer to make improved versions.
Northstar was installed at its first beta-release customer site this month, Wake Radiology (www.wakerad.com) in Raleigh, North Carolina. "My expectation is that the Northstar viewer is going to simplify the experience for my radiologists. The output from these AI algorithms are expected to far surpass what we could generate individually on any given day, for specific reports. Volumetric measurements and serial comparisons that could not be done or would take a lot of time to do individually should be automated with AI", said Dr. William Way, Chief Medical Officer of Wake Radiology. Dr. Way continued, "Having these results readily available and nicely integrated into our PACS and reporting workflows is vastly superior to what we are doing now."
"AI is important to where we are going as a radiology provider, and it is nice to be on the cutting edge", said Matt Dewey, Chief Information Officer of Wake Radiology. Matt continued, "Because algorithms work differently and each of them has different inputs and outputs, my radiologists would otherwise have to have a different way of working with each one. Northstar solves this problem by providing a simple and consistent way that our physicians work with the output of algorithms from many sources, and adapting itself to their personal preferences."
TeraRecon AI solutions will be demonstrated during the Society for Imaging Informatics in Medicine annual meeting, May 31st through June 2nd in National Harbor, Maryland at Booth #405. Online demonstrations and more information are available by contacting TeraRecon at firstname.lastname@example.org.
About TeraRecon (www.terarecon.com) TeraRecon is a leader in advanced visualization, image viewing, and post-processing. Our flagship product, iNtuition, consistently leads the advanced visualization category of the industry's leading independent technology analyst. We are committed to redefining advanced visualization by leveraging artificial intelligence, and to improving radiology workflow through personalized automation features that increase efficiency.
About EnvoyAI (www.envoyai.com) EnvoyAI facilitates the streamlined distribution and hospital implementation of trained machine learning algorithms via a vendor-neutral distribution platform. EnvoyAI provides a developer platform, integrations, and an open API for algorithm developers, technology partners, and end users. EnvoyAI assists research institutions and emerging AI companies in the translation and commercialization processes, starting with rapid deployment via a scalable, secure, cloud-based infrastructure with the ability to add local components to facilitate on-site deployments as well. EnvoyAI also works with distribution partners to make algorithms on the platform available to a very wide footprint of hospitals and, ultimately, to physicians.
About Wake Radiology ( www.wakerad.com ) Founded in 1953, Wake Radiology is the leading provider of outpatient medical imaging in Central North Carolina. Its physicians have been trained as experts in specific imaging specialties - ranging from breast cancer detection and pediatrics to sports medicine and neuroradiology - to accurately diagnose healthcare issues. Another hallmark of Wake Radiology is its commitment to low-dose imaging and the elimination of unnecessary or duplicate exams. This approach strives to improve patient outcomes and reduces the overall cost of healthcare. Wake Radiology is the region's largest outpatient imaging practice with nearly 50 radiologists who perform close to 600,000 procedures each year. It is the first outpatient imaging provider in the Triangle to earn the American College of Radiology's prestigious Breast Imaging Center of Excellence designation. Wake Radiology is an independent, locally owned and physician-led practice that actively supports the local community.
About CorStem (www.corstem.ai) Corstem is a machine learning and artificial intelligence software developer specialized in medical imaging analysis and computer vision. Founded in 2016, its AI-powered tools are setting the standard in dynamic cardiac analysis. Corstem enables a whole new level of efficiency and automation for diagnosis aid to save valuable physician and patient time.
IMPORTANT REGULATORY NOTICE: The TeraRecon Northstar and Corstem cardiac MR products mentioned herein are not for clinical use or sale at this time.
Press Inquiries US: 1-650-372-1100 | email@example.com
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: TeraRecon, Inc via Globenewswire
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Karolinska Development delays publication of its Annual Report for 2018 and changes date for the Annual General Meeting26.4.2019 08:00:00 CEST | Press release
STOCKHOLM, SWEDEN - 26 April 2019. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that The Board of Directors has decided to delay the publication of its Annual Report for 2018. Karolinska Development has changed the date for the Annual General Meeting to June 26, 2019. The date for publication of the Annual Report for 2018 has been changed from April 26 to April 30, 2019. Karolinska Development has changed the date for the Annual General Meeting from June 4 to June 26, 2019. Notice to the Annual General Meeting will be published in a separate press release. For more information, please contact: Viktor Drvota, CEO, Karolinska Development AB Phone: +46 73 982 52 02, e-mail: firstname.lastname@example.org Fredrik Järrsten, CFO, Karolinska Development AB Phone: +46 70 496 46 28, e-mail: email@example.com TO THE EDITORS About Karolinska Development AB Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investmen
Karolinska Development senarelägger publicering av årsredovisningen för 2018 och meddelar nytt datum för årsstämma26.4.2019 08:00:00 CEST | Pressmeddelande
STOCKHOLM, SVERIGE - 26 april 2019. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att styrelsen har beslutat att senarelägga publiceringen av årsredovisningen för 2018. Karolinska Development har ändrat datum för årsstämman till den 26 juni 2019. Publiceringen av årsredovisningen för 2018 flyttas från den 26 april till den 30 april 2019. Karolinska Development har ändrat datum för årsstämman från den 4 juni till den 26 juni 2019. Kallelse till årsstämman kommer att publiceras senare i ett separat pressmeddelande. För ytterligare information, vänligen kontakta: Viktor Drvota, vd, Karolinska Development AB Tel: +46 73 982 52 02, e-mail: firstname.lastname@example.org Fredrik Järrsten, finanschef, Karolinska Development AB Tel: +46 70 496 46 28, e-mail: email@example.com TILL REDAKTÖRERNA Om Karolinska Development AB Karolinska Development AB (Nasdaq Stockholm: KDEV) är ett nordiskt investmentbolag inom life science. Bolaget fokuserar p
Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CEST | Pressmeddelande
STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva
Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CEST | Press release
STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre
Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CEST | Pressmeddelande
Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201
Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CEST | Press release
Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom